Tenaya Therapeutics Inc (TNYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tenaya Therapeutics Inc (TNYA) has a cash flow conversion efficiency ratio of -0.188x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.60 Million) by net assets ($82.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tenaya Therapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
Tenaya Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tenaya Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tenaya Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tenaya Therapeutics Inc ranked by their cash flow conversion efficiency. See TNYA cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atrem S.A.
WAR:ATR
|
-0.108x |
|
Diamond Building Products Public Company Limited
BK:DRT
|
0.054x |
|
NH SPAC 2
KQ:206640
|
0.043x |
|
Journey Medical Corp
NASDAQ:DERM
|
-0.200x |
|
SR Bancorp, Inc. Common stock
NASDAQ:SRBK
|
0.019x |
|
CBO Territoria S.A.
PA:CBOT
|
0.039x |
|
Hannong Chem
KO:011500
|
0.058x |
|
Lyko Group A
ST:LYKO-A
|
0.368x |
Annual Cash Flow Conversion Efficiency for Tenaya Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tenaya Therapeutics Inc from 2019 to 2024. View current stock price of Tenaya Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.85 Million | $-90.50 Million | -0.975x | -33.13% |
| 2023-12-31 | $139.42 Million | $-102.07 Million | -0.732x | -70.63% |
| 2022-12-31 | $243.38 Million | $-104.42 Million | -0.429x | -96.52% |
| 2021-12-31 | $278.53 Million | $-60.81 Million | -0.218x | +14.11% |
| 2020-12-31 | $139.44 Million | $-35.45 Million | -0.254x | -146.14% |
| 2019-12-31 | $-43.74 Million | $-24.10 Million | 0.551x | -- |
About Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ve… Read more